4dd48c58-cb90-4197-ba50-2aaca555e6d1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 87
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.440
- FATTY_ACID_METABOLISM+0.400
- G2M_CHECKPOINT+0.360
- MITOTIC_SPINDLE+0.350
- PANCREAS_BETA_CELLS+0.350
- ANDROGEN_RESPONSE+0.330
- GLYCOLYSIS+0.320
- PEROXISOME+0.320
- E2F_TARGETS+0.300
- ADIPOGENESIS+0.290
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.130
- DNA_REPAIR-0.080
- COAGULATION-0.070
- ALLOGRAFT_REJECTION-0.060
- IL6_JAK_STAT3_SIGNALING-0.050
- KRAS_SIGNALING_DN-0.050
- TGF_BETA_SIGNALING-0.050
- IL2_STAT5_SIGNALING-0.040
- INTERFERON_GAMMA_RESPONSE-0.030
- MYOGENESIS-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 71423c68-fae7-472e-b291-a177a0e69538 | — | — | 0.780 |
| 2 | EA485E4A-5956-430C-8584-E14D865E3758 | — | — | 0.766 |
| 3 | 5282B52E-8573-4FC0-9BED-420AE3D2B096 | — | — | 0.723 |
| 4 | C7284164-EF9A-4BF0-AE88-571A0BA93E66 | — | — | 0.722 |
| 5 | 32CED7C6-C413-4B5C-8A49-8AA2C97E582D | — | — | 0.715 |
| 6 | 51A24E0F-CC2C-4CBF-B841-80A747297A42 | — | — | 0.712 |
| 7 | 387C53ED-A9ED-481F-87D9-87090B690E0E | — | — | 0.711 |
| 8 | TCGA-4Z-AA7Y-01A-11R-A39I-07 | — | — | 0.694 |
| 9 | GSM5359435 | — | — | 0.693 |
| 10 | CF764E50-B0F9-44DE-8B48-F8F5A8920240 | — | — | 0.687 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.440 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |